Barclays PLC Has $577,000 Position in Ocugen, Inc. (NASDAQ:OCGN)

Barclays PLC increased its position in shares of Ocugen, Inc. (NASDAQ:OCGN) by 104.3% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 581,087 shares of the company’s stock after buying an additional 296,654 shares during the quarter. Barclays PLC owned 0.20% of Ocugen worth $577,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Xponance Inc. bought a new stake in shares of Ocugen in the 2nd quarter worth approximately $25,000. Victory Capital Management Inc. bought a new position in Ocugen in the second quarter worth $51,000. E Fund Management Co. Ltd. bought a new position in Ocugen in the second quarter worth $75,000. SG Americas Securities LLC acquired a new stake in Ocugen during the third quarter worth $87,000. Finally, MetLife Investment Management LLC increased its holdings in Ocugen by 36.4% in the 3rd quarter. MetLife Investment Management LLC now owns 89,508 shares of the company’s stock valued at $89,000 after buying an additional 23,877 shares during the period. 10.27% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of research firms have recently commented on OCGN. HC Wainwright reaffirmed a “buy” rating and set a $7.00 price objective on shares of Ocugen in a report on Monday. Maxim Group began coverage on shares of Ocugen in a research report on Tuesday, October 15th. They issued a “buy” rating and a $4.00 price target for the company. Finally, Chardan Capital reaffirmed a “buy” rating and set a $6.00 price objective on shares of Ocugen in a report on Monday, November 18th.

Ocugen Stock Performance

Ocugen stock opened at $0.72 on Friday. Ocugen, Inc. has a 52-week low of $0.49 and a 52-week high of $2.11. The company has a debt-to-equity ratio of 0.04, a current ratio of 2.58 and a quick ratio of 2.58. The stock has a fifty day moving average price of $0.87 and a two-hundred day moving average price of $1.12. The firm has a market capitalization of $208.29 million, a P/E ratio of -3.97 and a beta of 3.85.

About Ocugen

Ocugen, Inc, a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve patients’ health. The company’s pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease.